Followers | 170 |
Posts | 8965 |
Boards Moderated | 0 |
Alias Born | 01/24/2011 |
Thursday, August 25, 2016 2:19:43 PM
I've used Visio in the past, but the image in that post was just an an Alt-PrintScreen capture pasted into MS Paint, cropped, and then annotated using the fairly primitive but adequate tools in that program.
The problem with the CBD space is that its fairly easy to enter if you can afford a CO2 extractor and a biochemist.
CVSI was an early entry, and perhaps if it hadn't initially partnered with Medical Marijuana, Inc, which IMO has really bad corporate governance and has screwed-up nearly every business arrangement it has ever made, it might have been able to get a better start and not have to build its own sales organization starting in late 2014.
Now it has a lot of competition from companies like Endoca, Bluebird Botanicals, Isodiol, etc, and I think there might be a company or two in South or Central America. There are even some "Mom & Pop" CBD manufacturers in states where the growing of industrial hemp for "research" purposes is permitted by state law.
That's probably why the company changed its business focus, as announced in the January 4, 2016 PR announcing the acquisition of CanX and the name change from CannaVest to CV Sciences:
http://www.otcmarkets.com/stock/CVSI/news/CannaVest-Corp--Acquires-CanX--Inc--and-Its-Subsidiary-Canabine--LLC--Announces-Name-Change-and-Appointment-of-New-Director?id=122480&b=y
Of course, drug development is costly, and they're not generating the funds from sales, so more convertible notes are issued.
"Soylent Green is people!!!"
Detective Robert Thorn: Telling uncomfortable truths since 2022
DRT is Charleton Heston's character in the 1973 movie, Soylent Green, set in the year 2022, and is not my real name
Recent CVSI News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 02:36:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:21:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 01:32:15 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM